临床泌尿外科杂志
臨床泌尿外科雜誌
림상비뇨외과잡지
JOURNAL OF CLINICAL UROLOGY
2001年
2期
68-69
,共2页
膀胱肿瘤%丝裂霉素C%卡介苗%交替灌注
膀胱腫瘤%絲裂黴素C%卡介苗%交替灌註
방광종류%사렬매소C%잡개묘%교체관주
目的：观察丝裂霉素C（MMC）和卡介苗（BCG）化学免疫预防膀胱癌术后复发的疗效。方法：对86例浅表性膀胱癌患者术后应用MMC 20 mg和BCG 60 mg，每周1次进行交替膀胱灌注，共灌注12次，以后每间隔3个月灌注1次，持续2年。结果：随访2.4～8年，平均4.8年，肿瘤复发率为8.1%。结论：MMC和BCG交替膀胱灌注可减少膀胱癌术后复发率。
目的：觀察絲裂黴素C（MMC）和卡介苗（BCG）化學免疫預防膀胱癌術後複髮的療效。方法：對86例淺錶性膀胱癌患者術後應用MMC 20 mg和BCG 60 mg，每週1次進行交替膀胱灌註，共灌註12次，以後每間隔3箇月灌註1次，持續2年。結果：隨訪2.4～8年，平均4.8年，腫瘤複髮率為8.1%。結論：MMC和BCG交替膀胱灌註可減少膀胱癌術後複髮率。
목적：관찰사렬매소C（MMC）화잡개묘（BCG）화학면역예방방광암술후복발적료효。방법：대86례천표성방광암환자술후응용MMC 20 mg화BCG 60 mg，매주1차진행교체방광관주，공관주12차，이후매간격3개월관주1차，지속2년。결과：수방2.4～8년，평균4.8년，종류복발솔위8.1%。결론：MMC화BCG교체방광관주가감소방광암술후복발솔。
Purpose:To investigate the clinical results of intravesical instillation with MMC and BCG for the prevention of postoperative recurrence of bladder tumor.Methods:86 cases of patients with superficial bladder cancer were included in this study. All patients received intravesical instillation of 20 mg MMC or 60mg BCG in turn once a week postoperatively, and persisted for 12 weeks. Then intravesical instillation was performed every 3 months, persisted for 2 years.Results: All patients have been followed up for 2.4 to 8 years, with a average of 4.8 years. The recurrent rate was 8.1%.Conclusions:Intravesical instillation of MMC and BCG in turn are effective for reducing the postoperative recurrence rate of bladder tumor.
